Market Chameleon (Fri, 9-Jan 3:58 AM ET)
Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
Business Wire (Fri, 9-Jan 8:05 AM ET)
Business Wire (Wed, 31-Dec 8:00 AM ET)
Business Wire (Wed, 3-Dec 4:01 PM ET)
Market Chameleon (Fri, 21-Nov 6:06 AM ET)
Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program
Business Wire (Thu, 20-Nov 4:01 PM ET)
Business Wire (Tue, 18-Nov 8:00 AM ET)
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Fri, 14-Nov 4:01 PM ET)
Business Wire (Thu, 13-Nov 8:30 AM ET)
Delcath Systems to Participate in Upcoming Investor Conferences
Business Wire (Thu, 6-Nov 4:01 PM ET)
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Delcath Systems trades on the NASDAQ stock market under the symbol DCTH.
As of January 20, 2026, DCTH stock price declined to $10.20 with 411,320 million shares trading.
DCTH has a beta of 1.49, meaning it tends to be more sensitive to market movements. DCTH has a correlation of 0.20 to the broad based SPY ETF.
DCTH has a market cap of $353.94 million. This is considered a Small Cap stock.
Last quarter Delcath Systems reported $21 million in Revenue and $.02 earnings per share. This beat revenue expectation by $12 million and exceeded earnings estimates by $.07.
In the last 3 years, DCTH traded as high as $18.23 and as low as $2.25.
The top ETF exchange traded funds that DCTH belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
DCTH has underperformed the market in the last year with a return of -25.4%, while the SPY ETF gained +15.6%. In the last 3 month period, DCTH fell short of the market, returning -17.5%, while SPY returned +2.8%. However, in the most recent 2 weeks DCTH has outperformed the stock market by returning +2.5%, while SPY returned -0.9%.
DCTH support price is $10.13 and resistance is $10.61 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DCTH shares will trade within this expected range on the day.
